Sign up for Table of Contents Alerts.

Email this page

Print this page

Perspectives

IL-4-mediated drug resistance in colon cancer stem cells

Matilde Todaro, Mileidys Perez Alea, Alessandro Scopelliti, Jan Paul Medema and Giorgio Stassi

Purchase article for $19

Subscribe to this journal for $129/year

Cancer stem cells are defined as cells able to both extensively self-renew and differentiate into progenitors. Cancer stem cells are thus likely to be responsible for maintaining or spreading a cancer, and may be the most relevant targets for cancer therapy. The CD133 glycoprotein was recently described as a reliable cancer stem-like cell marker in colon carcinoma. CD133+ cells are both necessary and sufficient to initiate tumour growth in animal models. The CD133+ cell population and spheroid cultures contain cells expressing the stem cell marker Musashi-1 which is involved in maintenance of stem cell fate in several tissues and importantly, this expression is maintained in stem-like cells derived from xenografted tumours. Here we discuss the potential use of the CD133 antigen in concert with Musashi-1 as markers to identify the colon cancer stem cell population. Since the up-regulation of IL-4 cytokine was recently demonstrated to constitute an important mechanism that protects the tumorigenic CD133+ cells from apoptosis, the potential benefits of standard chemotherapeutic treatments in combination with IL-4 inhibitors in the context of human colon carcinoma, are also discussed.

Authors

Matilde Todaro

Cellular and Molecular Pathophysiology Laboratory; Palermo, Italy

Mileidys Perez Alea

Cellular and Molecular Pathophysiology Laboratory; Palermo, Italy

Alessandro Scopelliti

Cellular and Molecular Pathophysiology Laboratory; Palermo, Italy

Jan Paul Medema

Academic Medical Center; Amsterdam; The Netherlands

Giorgio Stassi

Cellular and Molecular Pathophysiology Laboratory; Palermo, Italy

Purchase article for $19

Subscribe to this journal for $129/year